Epstein Secrets

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

sing 60 hourly data points, correlation has moved from around -80% a month ago to =ero now. This means the volatility of risk parity portfolios are increasin= and rebalancing is required. Chart Two: Investm=nt Grade ETF, LQD, is at the top of a long term channel with shares outsta=ding around an all time

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

sing 60 hourly data points, correlation has moved from around -80% a month ago to =ero now. This means the volatility of risk parity portfolios are increasin= and rebalancing is required. </=pan> Chart Two: Investm=nt Grade ETF, LQD, is at the top of a long term channel with shares outsta=ding around an a

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

sing 60 hourly data points, correlation has moved from around -80% a month ago to =ero now. This means the volatility of risk parity portfolios are increasin= and rebalancing is required. Chart Two: Investm=nt Grade ETF, LQD, is at the top of a long term channel with shares outsta=ding around an all time